Our Strategic
Priorities
More energy –
Growing and delivering

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. To achieve this, we will develop Idorsia into one of Europe’s leading biopharmaceutical companies, with a strong scientific core.
We have identified five key strategic priorities to ensure the company’s success in the mid-term.

Promising compounds

Idorsia aims to deliver at least three products to market with the potential to significantly change treatment options in their target disease, resulting in assets with major commercial potential.
We have a diversified and balanced clinical development pipeline that cover multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.
We bring new perspectives to the development of innovative compounds, challenging accepted paradigms to answer the questions that matter to patients.
“With patients at the heart of our process, our key assets have the potential to transform treatment in the target indications.”
- Guy Braunstein, Head of Global Clinical Development